Cedar Capital LLC bought a new position in shares of Merck & Company, Inc. (NYSE:MRK) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 3,631 shares of the company’s stock, valued at approximately $233,000.

Several other institutional investors also recently made changes to their positions in the company. RB Capital Management LLC raised its position in shares of Merck & Company, Inc. by 0.5% during the second quarter. RB Capital Management LLC now owns 4,587 shares of the company’s stock worth $294,000 after purchasing an additional 23 shares during the period. Baystate Wealth Management LLC raised its position in shares of Merck & Company, Inc. by 0.4% during the second quarter. Baystate Wealth Management LLC now owns 6,470 shares of the company’s stock worth $405,000 after purchasing an additional 27 shares during the period. Bath Savings Trust Co raised its position in shares of Merck & Company, Inc. by 0.5% during the second quarter. Bath Savings Trust Co now owns 5,427 shares of the company’s stock worth $348,000 after purchasing an additional 28 shares during the period. Camelot Portfolios LLC raised its position in shares of Merck & Company, Inc. by 0.4% during the first quarter. Camelot Portfolios LLC now owns 7,771 shares of the company’s stock worth $494,000 after purchasing an additional 33 shares during the period. Finally, Stillwater Investment Management LLC raised its position in shares of Merck & Company, Inc. by 0.8% during the second quarter. Stillwater Investment Management LLC now owns 4,621 shares of the company’s stock worth $296,000 after purchasing an additional 38 shares during the period. 72.98% of the stock is currently owned by institutional investors.

Shares of Merck & Company, Inc. (NYSE:MRK) traded down $0.02 during midday trading on Monday, reaching $54.35. The company’s stock had a trading volume of 4,341,200 shares, compared to its average volume of 9,568,852. The company has a quick ratio of 1.16, a current ratio of 1.43 and a debt-to-equity ratio of 0.57. Merck & Company, Inc. has a 1 year low of $53.63 and a 1 year high of $66.80. The stock has a market capitalization of $148,073.14, a P/E ratio of 13.97, a P/E/G ratio of 2.34 and a beta of 0.78.

Merck & Company, Inc. (NYSE:MRK) last issued its earnings results on Friday, October 27th. The company reported $1.11 EPS for the quarter, beating analysts’ consensus estimates of $1.03 by $0.08. Merck & Company, Inc. had a return on equity of 27.08% and a net margin of 11.60%. The firm had revenue of $10.33 billion for the quarter, compared to the consensus estimate of $10.54 billion. During the same quarter in the previous year, the company posted $1.07 earnings per share. The business’s quarterly revenue was down 2.0% compared to the same quarter last year. equities research analysts forecast that Merck & Company, Inc. will post 3.95 EPS for the current fiscal year.

In other Merck & Company, Inc. news, Director Thomas H. Glocer sold 5,000 shares of the business’s stock in a transaction dated Wednesday, November 8th. The stock was sold at an average price of $56.20, for a total value of $281,000.00. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 0.25% of the company’s stock.

MRK has been the topic of a number of research analyst reports. BMO Capital Markets set a $70.00 price target on Merck & Company, Inc. and gave the company a “buy” rating in a report on Wednesday, October 11th. UBS AG lifted their price target on Merck & Company, Inc. from $70.00 to $72.00 and gave the company a “buy” rating in a report on Monday, July 31st. Citigroup Inc. upgraded Merck & Company, Inc. from a “neutral” rating to a “buy” rating and set a $72.00 price target on the stock in a report on Wednesday, October 18th. J P Morgan Chase & Co set a $70.00 price target on Merck & Company, Inc. and gave the company a “buy” rating in a report on Sunday, October 29th. Finally, Sanford C. Bernstein reiterated a “buy” rating and set a $64.00 price target on shares of Merck & Company, Inc. in a report on Wednesday, November 15th. Two analysts have rated the stock with a sell rating, ten have issued a hold rating and ten have issued a buy rating to the company. Merck & Company, Inc. presently has an average rating of “Hold” and a consensus price target of $66.44.

WARNING: This news story was posted by Watch List News and is the property of of Watch List News. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark and copyright legislation. The original version of this news story can be read at https://www.watchlistnews.com/cedar-capital-llc-takes-position-in-merck-company-inc-mrk/1729353.html.

About Merck & Company, Inc.

Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Company, Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Company, Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Company Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.